Postprandial dysfunction in fatty liver disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,28 MB, PDF-dokument

Fatty liver disease has mainly been characterized under fasting conditions. However, as the liver is essential for postprandial homeostasis, identifying postprandial disturbances may be important. Here, we investigated postprandial changes in markers of metabolic dysfunction between healthy individuals, obese individuals with non-alcoholic fatty liver disease (NAFLD) and patients with cirrhosis. We included individuals with biopsy-proven NAFLD (n = 9, mean age 50 years, mean BMI 35 kg/m2, no/mild fibrosis), cirrhosis with hepatic steatosis (n = 10, age 62 years, BMI 32 kg/m2, CHILD A/B) and healthy controls (n = 10, age 23, BMI 25 kg/m2), randomized 1:1 to fasting or standardized mixed meal test (postprandial). None of the patients randomized to mixed meal test had type 2 diabetes (T2D). Peripheral blood was collected for 120 min. After 60 min, a transjugular liver biopsy and liver vein blood was taken. Plasma levels of glucose, insulin, C-peptide, glucagon, and fibroblast growth factor 21 (FGF21) were measured. Postprandial peak glucose and C-peptide were significantly increased in NAFLD, and cirrhosis compared with healthy. Patients with NAFLD and cirrhosis had hyperglucagonemia as a potential sign of glucagon resistance. FGF21 was increased in NAFLD and cirrhosis independent of sampling from the liver vein versus peripheral blood. Glucagon levels were higher in the liver vein compared with peripheral blood. Patients with NAFLD and cirrhosis without T2D showed impaired glucose tolerance, hyperinsulinemia, and hyperglucagonemia after a meal compared to healthy individual. Postprandial characterization of patients with NAFLD may be important to capture their metabolic health.

OriginalsprogEngelsk
Artikelnummere15653
TidsskriftPhysiological Reports
Vol/bind11
Udgave nummer8
Antal sider15
ISSN2051-817X
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
The authors thank Stefan Stender (Department of Clinical Biochemistry, Copenhagen University Hospital—Rigshospitalet, University of Copenhagen, Denmark) for genotyping and helpful discussions, Christine Rasmussen (Department of Clinical Biochemistry, Bispebjerg Hospital, Copenhagen University Hospital Denmark) for excellent laboratory assistance in performing ELISA and technical staff at the department of Clinical Physiology for helpful assistance during the invasive procedures.

Funding Information:
The study and Josephine Grandt, Anne‐Sophie H. Jensen, and Nicolai J. Wewer Albrechtsen were supported by the Novo Nordisk Foundation Excellence Emerging Investigator Grant—Endocrinology and Metabolism (Application No. NNF19OC0055001), the European Foundation for the Study of Diabetes Future Leader Award (NNF21SA0072746) and Independent Research Fund Denmark, Sapere Aude (1052‐00003B). The Novo Nordisk Foundation Center for Protein Research is supported financially by the Novo Nordisk Foundation (NNF14CC0001).

Publisher Copyright:
© 2023 The Authors. Physiological Reports published by Wiley Periodicals LLC on behalf of The Physiological Society and the American Physiological Society.

ID: 347107229